Clinical Trial Search

Primary: Change in Mean Trough Levels of 17-OHPC in the Three Groups at 20-22 Weeks, 27-29 Weeks and 34-36 Weeks. — 10.1; 13.0; 18.0; 11.5 ng/ml

Primary: Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg) — -2.59; -2.59; -0.93 Percentage of HbA1c — p=<0.001

Primary: Cohort 1: Number of Participants Who Achieved Sitting Alone for at Least 30 Seconds — 14 Participants

Primary: Percentage of Participants With Clinical Remission at Week 52 — 61.0; 64.9 percentage of participants

Primary: Number of Participants With Return of Spontaneous Circulation — 100; 86 participants

Primary: Number of Participants Who Achieved Sitting Alone for at Least 10 Seconds — 1 Participants

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAE) — 673; 527; 448; 575 Participants

Primary: Change From Baseline in the Acceptability of Intervention Measure (AIM) Total Score in Staff Study Participants at Month 4 — 0.00 Scores on a scale

Primary: Treatment Efficacy of Pharyngeal Gonorrhea as Defined as the Proportion of Study Participants With Positive Pharyngeal Gonorrhea Culture at of Enrollment Whose Test of…

Primary: Time to Alleviation of COVID-19-related Symptoms by Day 30 — 19.0; 19.0 days

Primary: Ocular Discomfort — 0.07; -0.04 score on a scale

Primary: Number of Participants With Respiratory Syncytial Virus (RSV) Hospitalization — 80; 21 Participants — p=<0.001

Primary: Progression Free Survival (PFS) Based on Independent Central Review. — 21.5; 13.8; 23.2; 13.8 Months — p=0.000002

Primary: Annualized Height Velocity at 52 Weeks for Weekly Lonapegsomatropin and Daily hGH Treatment Groups — 11.17; 10.31 cm/year — p=0.0088

Primary: Number of Participants With Treatment-Emergent Adverse Events [Safety and Tolerability] — 83; 6; 1; 0 Participants